/
ATNM
$0.99+$0.00 (+0.00%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$31.1M
31M shares
52-week range
$0.94 – $1.89
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
0.85%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-6.75
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.1M | $1.0M | $81.0K | $0 | $90.0K |
| Cost of revenue | $50.7K | $420.1K | $447.0K | $524.0K | $0 | $0 | $811.0K | $0 |
| Gross profit | −$50.7K | −$420.1K | −$447.0K | $620.0K | $1.0M | $81.0K | −$811.0K | $90.0K |
| Gross margin | — | — | — | 54.2% | 100.0% | 100.0% | — | 100.0% |
| R&D | $17.1M | $16.5M | $16.1M | $17.5M | $23.1M | $38.7M | $30.0M | $21.1M |
| Operating income | −$23.8M | −$22.1M | −$22.4M | −$25.0M | −$34.1M | −$51.9M | −$42.1M | −$36.2M |
| EBITDA | −$23.8M | −$21.5M | −$21.8M | −$24.3M | −$32.3M | −$48.0M | −$37.4M | −$33.1M |
| Net income | −$23.7M | −$21.9M | −$22.2M | −$24.8M | −$33.0M | −$48.8M | −$38.2M | −$33.9M |
| Net margin | — | — | — | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| EPS (diluted) | -6.69 | -4.37 | -1.83 | -1.20 | -1.37 | -1.83 | -1.27 | -1.09 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-0.85 | $-0.85–$-0.85 | 1 |
| 2027 | $19M | $-0.82 | $-0.82–$-0.82 | 2 |
| 2028 | $35M | $-0.29 | $-0.81–$0.13 | 3 |
| 2029 | $121M | $1.59 | $1.59–$1.59 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.48
Price
$0.99
Implied upside
+50%
Peer comparison
Actinium Pharmaceuticals, Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
www.actiniumpharma.com- Employees
- 25
- IPO / List date
- Jul 19, 2007
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds ATNM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 471,600 | $469.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-08-11 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded ATNM yet.
